5.3.3 Viral hepatitis

5.3.3.1 Chronic hepatitis B

Entecavir
  • Tablets 500 micrograms, 1mg
  • Oral solution 50 micrograms

Notes

  1. NICE TA153: Entecavir for chronic hepatitis B (August 2008)
Telbivudine
  1. Not recommended for people with chronic hepatitis B (see NICE TA154, August 2008)

5.3.3.2 Chronic hepatitis C

MHRA Drug Safety Update (October 2018): Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels. Monitor thyroid-stimulating hormone (TSH) in patients treated with levothyroxine for at least the first month after the start and end of ritonavir treatment

MHRA Drug Safety Update (December 2018): Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes

Daclatasvir
  • Tablets 30mg, 60mg

Notes

  1. NICE TA364: Daclatasvir recommended for treating hepatitis C (NHS England commissioned) (November 2015)
Dasabuvir
  • Tablets 250mg

Notes

  1. NICE TA365: Ombitasvir-paritaprevir-ritonavir (Viekirax®) with or without dasabuvir (Exviera®) is recommended within its marketing authorisation, as an option for treating genotype 1 or 4 chronic hepatitis C in adults (NHS England commissioned) (November 2015).
Elbasvir-grazoprevir
  • Tablets 50mg/100mg

Notes

  1. NICE TA413 Elbasvir-grazoprevir recommended for treating chronic hepatitis C (NHS England commissioned) (October 2016)
Glecaprevir-pibrentasvir
  • Tablets modified-release 100mg/40mg

Notes

  1. NICE TA499: Glecaprevir–pibrentasvir is recommended as an option for treating chronic hepatitis C (January 2018)
Harvoni®
  • Tablets ledipasvir 90mg/ sofosbuvir 400mg

Notes

  1. NICE TA363: Ledipasvir-sofosbuvir for treating chronic hepatitis C (NHS England commissioned) (November 2015)
Simeprevir
  • Capsules 150mg

Notes

  1. NICE TA331: Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C (February 2015)
Sofosbuvir
  • Tablets 400mg

Notes

  1. NICE TA330: Sofosbuvir for treating chronic hepatitis C (February 2015)
Sofosbuvir-velpatasvir
  • Tablets sofosbuvir 400mg/ velpatasvir 100mg

Notes

  1. NICE TA430: Sofosbuvir–velpatasvir is recommended as an option for treating chronic hepatitis C in adults (January 2017). Commissioned by NHS England.
Sofosbuvir-velpatasvir-voxilaprevir
  • Tablets sofosbuvir 400mg/ velpatasvir 100mg/ voxilaprevir 100mg

Notes

  1. NICE TA507: Sofosbuvir-velpatasvir-voxilaprevir is recommended as an option for treating chronic hepatitis C in adults (NHS England commissioned) (February 2018)
Viekirax®
  • Tablets ombitasvir 12.5mg/ paritaprevir 75mg/ ritonavir 50mg

Notes

  1. NICE TA 365: Ombitasvir-paritaprevir-ritonavir (Viekirax®) with or without dasabuvir (Exviera®) is recommended within its marketing authorisation, as an option for treating genotype 1 or 4 chronic hepatitis C in adults (NHS England commissioned) (November 2015)

 

Home > Formulary > Chapters > 5. Infections > 5.3 Antiviral drugs > 5.3.3 Viral hepatitis

 

  • First line
  • Second line
  • Specialist
  • Hospital